Table 2.

Clinical Characteristics of DOAC Cases Associated with CSVV in Sentinel System

Patient Characteristic	N	%
Number of unique patients	3659
Demographics
Mean Age, (±SD)	75.2 (±10.3)
Age
30–39	33	0.9
40–49	71	1.9
50–59	223	6.1
60–69	642	17.5
70+	2690	73.5
Sex
Male	1793	49.0
Female	1865	51.0
Any DOAC dispensing, up to 10 days prior to CSVV diagnosis	3112	85.1
Clinical Characteristics
Atrial Fibrillation, up to 183 days before CSVV diagnosis	2876	78.6
Skin biopsy, up to 14 days before or after CSVV diagnosis	704	19.2
Prednisone and/or Prednisolone treatment, up to 90 days after CSVV diagnosis	1123	30.7
Prednisone and/or Prednisolone treatment, up to 90 days after CSVV biopsy, up to 14 days before or after CSVV diagnosis	244	6.7
Cutaneous Small Vessel Vasculitis Coding on day of Diagnosisa
Vascular disorders of skin	1040	28.4
Henoch-Schonlein allergic purpura	752	20.6
Vasculitis limited to the skin, unspecified	598	16.3
Allergic purpura	378	10.3
Other specified hypersensitivity angiitis	368	10.1
Other vasculitis limited to the skin, specified NEC	265	7.2
Hypersensitivity angiitis	225	6.1
Hypersensitivity angiitis, unspecified	138	3.8

^aCounts may sum to greater than the total number of unique patients due to patients with multiple valid index-defining codes on their index date.